ReviewBiological research2021
The therapeutic potential of mesenchymal stem cells in treating osteoporosis.
Review in Biological research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Stage-specific biomimetic nanoparticles reprogram osteoblast-adipocyte equilibrium for targeted osteoporosis therapy.Bioactive materials · 2026Article
- Targeting cellular senescence in diabetic kidney disease: potential of regenerative, cell-based therapies and other senotherapeutic approaches.Kidney international · 2026Review
- MYC-SEPT11 Axis Promotes osteoblast differentiation and bone formation via PI3K/AKT and RhoA/ROCK signaling pathways.Functional & integrative genomics · 2026Article
- miR-1290 serves as a potential biomarker for osteoporotic fracture and regulates osteoblast function by targeting KDM5A.Journal of orthopaedic surgery and research · 2026Article
- Enhancing osteoporosis treatment: emerging roles of engineered exosomes in bone regeneration and repair.Journal of translational medicine · 2026Review
- Global knowledge graph of osteoporosis biomarkers based on large language model embeddings and complex network algorithms.Frontiers in endocrinology · 2026Article
- Immunohistochemical evaluation of bone regeneration induced by human umbilical cord mesenchymal stem cells around implants in an osteoporotic rat model.Journal of dental sciences · 2026Article
- Genetically reprogrammed BMSCs with Lamin B1 depletion enhance bone regeneration for osteoporosis therapy.Frontiers in bioengineering and biotechnology · 2026Article
- Increased BMP/SMAD Signaling by PD-MSCs Promotes Bone Formation in an Ovariectomized Mouse Model of Osteoporosis.International journal of molecular sciences · 2025Article
- Mettl7a alleviated bone loss in osteoporosis mice by targeting the O-GlcNAcylation of Bsp via m6A methylation.Stem cells translational medicine · 2025Article
- An Alternative to Biliverdin, Mesobiliverdin IXα and Mesobiliverdin-Enriched Microalgae: A Review on the Production and Applications of Mesobiliverdin-Related Products.Molecules (Basel, Switzerland) · 2025Review
- Osteogenic differentiation of mesenchymal stem cells in cell-laden culture of self-assembling peptide hydrogels.OpenNano · 2025Article
- Transcription factor SMAD5 upregulates ALG5 to alleviate osteoporosis development by inducing osteogenic differentiation.Journal of orthopaedics · 2025Article
- iPSCs-derived iMSCs prevent osteoporotic bone loss and affect bone metabolites in ovariectomized mice.Journal of cellular and molecular medicine · 2024Article
- "Three birds, one stone" strategy of NIR-responsive CO/HMaterials today. Bio · 2024Article
- How to enhance MSCs therapeutic properties? An insight on potentiation methods.Stem cell research & therapy · 2024Review
- PMAIP1 regulates autophagy in osteoblasts via the AMPK/mTOR pathway in osteoporosis.Human cell · 2024Article
- Comparison of the therapeutic effects of mesenchymal stem cells derived from human dental pulp (DP), adipose tissue (AD), placental amniotic membrane (PM), and umbilical cord (UC) on postmenopausal osteoporosis.Frontiers in pharmacology · 2024Article
- Network pharmacology identifies fisetin as a treatment for osteoporosis that activates the Wnt/β-catenin signaling pathway in BMSCs.Journal of orthopaedic surgery and research · 2023Article
- Mesenchymal stem/stromal cells-derived exosomes for osteoporosis treatment.World journal of stem cells · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
Osteoporosis (OP), a common systemic metabolic bone disease, is characterized by low bone mass, increasing bone fragility and a high risk of fracture. At present, the clinical treatment of OP mainly involves anti-bone resorption drugs and anabolic agents for bone, but their long-term use can cause serious side effects. The development of stem cell therapy and regenerative medicine has provided a new approach to the clinical treatment of various diseases, even with a hope for cure. Recently, the therapeutic advantages of the therapy have been shown for a variety of orthopedic diseases. However, these stem cell-based researches are currently limited to animal models; the uncertainty regarding the post-transplantation fate of stem cells and their safety in recipients has largely restricted the development of human clinical trials. Nevertheless, the feasibility of mesenchymal stem cells to treat osteoporotic mice has drawn a growing amount of intriguing attention from clinicians to its potential of applying the stem cell-based therapy as a new therapeutic approach to OP in the future clinic. In the current review, therefore, we explored the potential use of mesenchymal stem cells in human OP treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.